Early phase I and II studies showed a trend toward favorable responses of systemically administered IL-10 in psoriasis and Crohn’s disease patients, but larger studies revealed only a slight clinical benefit, due to the double anti- and pro-inflammatory properties of this cytokine (43, 195). Here, IL10 is linked to Crohn disease.